免疫腫瘍学（IO）市場 - テーマ別インテリジェンス

当レポートでは、免疫腫瘍学（IO）市場について調査し、腫瘍免疫学の概要と業界動向、上市済みおよびパイプライン薬剤の概要、課題とアンメットニーズなどについてまとめています。

目次

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 腫瘍免疫学の概要

• IOとは何か
• 規制当局による腫瘍免疫学とは何か
• 世界の腫瘍免疫学開発の最も重要なマイルストーン
• 主要なTwitterチャット

第4章 動向

• 業界の動向-二重特異性抗体
• 業界の動向-癌ワクチン
• 業界の動向-細胞治療
• 業界の動向-チェックポイントモジュレータ
• 業界の動向-サイトカイン
• 業界の動向-腫瘍溶解性ウイルス
• 規制の動向

第5章 バリューチェーン

• 癌免疫学のバリューチェーン
• 二重特異性抗体
• 癌ワクチン
• 細胞療法
• チェックポイントモジュレータ
• 次世代サイトカイン
• 腫瘍溶解性ウイルス
• 臨床試験における腫瘍免疫学

第6章 上市済み製品

• 主要8ヶ国市場で販売される癌免疫学製品
• IOエージェントの総市場規模
• 2022年に最も収益の高いIO治療薬10件
• 主要8ヶ国市場の主要なチェックポイントモジュレータ
• 主要8ヶ国市場の主要なBiTE
• 主要8ヶ国市場における主要な癌ワクチンと腫瘍溶解性ウイルス
• 主要8ヶ国市場における最先端の細胞療法

第7章 パイプライン製品

• 主要8ヶ国市場のIOパイプライン製品
• 処方医によるIO薬剤の将来の見通し
• 上位3つのパイプライン候補のコンセンサス予測売上高
• 予測される最も収益の高い二重特異性抗体製品
• 予測される最も収益の高いワクチン製品
• 予測される最も収益の高い細胞治療製品
• 予測される最も収益の高いチェックポイント変調製品
• 予測される最も収益の高いサイトカイン製品
• 予測される最も収益の高い腫瘍溶解性ウイルス製品

第8章 市場分析

第9章 規制と市場アクセス

第10章 機会、課題、アンメットニーズ

第11章 企業

• 医薬品開発スコアカード
• 現在の主要企業-Novartis
• 現在の主要企業-Merck &Co.
• 現在の主要企業-Gilead Sciences
• 現在の主力選手-Roche
• 現在の主要企業-BMS
• 現在の主要企業-AstraZeneca
• 現在の主要企業-Sanofi
• 現在の主要企業-Amgen
• 現在の主要企業-Dendreon Pharmaceuticals
• 現在の主要企業-Legend Biotech
• 現在の主要企業-Johnson & Johnson
• 現在の主力企業-Daiichi-Sankyo
• 現在の主力選手-Kite
• 現在の主要企業-Regeneron
• パイプラインの強さに基づく将来の参入企業-Genmab
• パイプラインの強さに基づく将来の参入企業-Iovance Therapeutics
• パイプラインの強さに基づく将来の参入企業-Replimune
• パイプラインの強さに基づく将来の参入企業-VBI Vaccines
• パイプラインの強さに基づく将来の参入企業-Jounce Therapeutics
• パイプラインの強さに基づく将来の参入企業-Oncosec
• パイプラインの強さに基づいた将来の参入企業-Abbvie
• パイプラインの強さに基づく将来の参入企業-BioNTech
• パイプラインの強さに基づく将来の参入企業-Greenwich LifeSciences
• パイプラインの強さに基づく将来の参入企業-CRISPR Therapeutics
• パイプラインの強さに基づく将来の参入企業-Allogene Therapeutics
• パイプラインの強さに基づく将来の参入企業-Xilio Therapeutics
• パイプラインの強さに基づく将来の参入企業-Candel Therapeutics

第12章 付録

第13章 お問い合わせ

Abstract

This report includes coverage of immuno-oncology overview, trends, value chain, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation to remain the most valuable IO sector. 2022-23 has seen some IO success, but no major IO breakthrough has happened. Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Key Highlights

Forecast includes 8 countries

Forecast covers 2022-2028

Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN IMMUNO-ONCOLOGY MARKET ASSESSMENT AND FORECAST ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Immuno-Oncology Overview

• 3.1. What is IO?
• 3.2. What is Immuno-oncology According to Regulators?
• 3.3. Most Important Milestones of Immuno-oncology Development Globally
• 3.4. Key Twitter Chat

4. Trends

• 4.1. Industry Trends - Bispecific Antibodies
• 4.2. Industry Trends - Cancer Vaccines
• 4.3. Industry Trends - Cell Therapies
• 4.4. Industry Trends - Checkpoint Modulators
• 4.5. Industry Trends - Cytokines
• 4.6. Industry Trends - Oncolytic Viruses
• 4.7. Regulatory Trends

5. Value Chain

• 5.1 Immuno-oncology Value Chain
• 5.2 Bispecific Antibodies
• 5.3 Cancer Vaccines
• 5.4 Cell Therapies
• 5.5 Checkpoint Modulators
• 5.6 Next-generation Cytokines
• 5.7 Oncolytic Viruses
• 5.8 Immuno-oncology in Clinical Trials

6. Marketed Products

• 6.1. Immuno-Oncology Marketed Products in the 8MM
• 6.2. Total Market Size for IO Agents
• 6.3. 10 Highest-Grossing IO Treatments in 2022
• 6.4. Leading Checkpoint Modulators in the 8MM
• 6.5. Leading BiTEs in the 8MM
• 6.6. Leading Cancer Vaccines and Oncolytic Viruses in the 8MM
• 6.7. Leading Cell Therapies in the 8MM

7. Pipeline Products

• 7.1. IO Pipeline Products in the 8MM
• 7.2. Future Outlook of IO Agents, According to High-Prescribing Physicians
• 7.3. Consensus Forecast Sales for the Top Three Pipeline Candidates
• 7.4. The Forecast Highest-Grossing Bispecific Antibody Products
• 7.5. The Forecast Highest-Grossing Vaccine Products
• 7.6. The Forecast Highest-Grossing Cell Therapy Products
• 7.7. The Forecast Highest-Grossing Checkpoint Modulator Products
• 7.8. The Forecast Highest-Grossing Cytokine Products
• 7.9. The Forecast Highest-Grossing Oncolytic Virus Products

8. Market Analysis

• 8.1. Market Analysis and Forecast of the Six Classes of IO Agents
• 8.2. Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
• 8.3. Latest Strategic Partnership Deals in the IO Space
• 8.4. Top 10 Mergers and Acquisitions that Include IO Assets: 2018-2023
• 8.5. Latest Mergers and Acquisitions that Include IO Assets

9. Regulatory and Market Access

• 9.1. IO in Clinical Trials
• 9.2. Endpoints in IO Clinical Trials - KOL Perspective
• 9.3. Challenges in IO Clinical Trials - KOL Perspective
• 9.4. Regulatory and Market Access - US
• 9.5. Regulatory and Market Access - EU
• 9.6. Regulatory and Market Access - Japan
• 9.7. Regulatory and Market Access - China
• 9.8. Early Access Schemes
• 9.9. Barriers to Access According to High Prescribers

10. Opportunities, Challenges, and Unmet Needs

• 10.1. Bispecific Antibodies
• 10.2. Cancer Vaccines
• 10.3. Cell Therapies
• 10.4. Checkpoint Modulators
• 10.5. Cytokines
• 10.6. Oncolytic Viruses
• 10.7. Clinical Unmet Needs in IO - Gap Analysis
• 10.8. Commercial Unmet Needs in Immuno-oncology - Gap Analysis
• 10.9. Unmet Needs - KOL Perspective
• 10.10 . Unmet Needs According to High Prescribers
• 10.11 R&D Strategies
• 10.12 Opportunities for the Industry - Modern Approaches & Collaboration
• 10.13 Closing Remarks - In Their Words

11. Companies

• 11.1. Drug Development Scorecard
• 11.2. Current Major Players - Novartis
• 11.3. Current Major Players - Merck & Co.
• 11.4. Current Major Players - Gilead Sciences
• 11.5. Current Major Players - Roche
• 11.6. Current Major Players - BMS
• 11.7. Current Major Players - AstraZeneca
• 11.8. Current Major Players - Sanofi
• 11.9. Current Major Players - Amgen
• 11.10. Current Major Players - Dendreon Pharmaceuticals
• 11.11. Current Major Players - Legend Biotech
• 11.12. Current Major Players - Johnson & Johnson
• 11.13. Current Major Players - Daiichi-Sankyo
• 11.14. Current Major Players - Kite
• 11.15. Current Major Players - Regeneron
• 11.16. Future Players Based on Pipeline Strength - Genmab
• 11.17. Future Players Based on Pipeline Strength - Iovance Therapeutics
• 11.18. Future Players Based on Pipeline Strength - Replimune
• 11.19. Future Players Based on Pipeline Strength - VBI Vaccines
• 11.20. Future Players Based on Pipeline Strength - Jounce Therapeutics
• 11.21. Future Players Based on Pipeline Strength - Oncosec
• 11.22. Future Players Based on Pipeline Strength - Abbvie
• 11.23. Future Players Based on Pipeline Strength - BioNTech
• 11.24. Future Players Based on Pipeline Strength - Greenwich LifeSciences
• 11.25. Future Players Based on Pipeline Strength - CRISPR Therapeutics
• 11.26. Future Players Based on Pipeline Strength - Allogene Therapeutics
• 11.27. Future Players Based on Pipeline Strength - Xilio Therapeutics
• 11.28. Future Players Based on Pipeline Strength - Candel Therapeutics

12. Appendix

• 12.1. Sources
• 12.2. Primary Research
• 12.3. Key Themes Impacting the Pharmaceutical Industry
• 12.4. Our Thematic Research Methodology
• 12.5. About the Authors

13. Contact Us